Pharmacogenomics - tailoring drug treatments to individuals based on their genetics - is on the cusp of transforming drug ...

Our policy briefings and explainers are part of our horizon-scanning programme to identify those novel technologies showing greatest promise for health research and care. Succinct and accessible, they ...

Chantal is a Senior Policy Analyst contributing to many of PHG foundations projects including B-CAST, polygenic scores and Innovative Science. As a senior analyst she supports the science team in ...

AI and its potential impact on genomics research and clinical practice was peppered throughout this year's Festival of Genomics ...

‘While molecular biomarkers such as genetics have proved valuable in the management of many diseases, the dynamic information provided by many physiological biomarkers will complement, enhance and ...

Clinical trials for exa-cel have shown promising results that it has been authorised by the FDA and MHRA for use in beta thalassemia and sickle cell disease. These successes make CRISPR technology, as ...

In Host genomics: lessons for infectious disease, we explore the potential of this complex field in tackling infectious disease. Based on our investigation of four major pathogens, we make ...

Dr. Khoury is the founding Director of the Office of Public Health Genomics at the U.S. Centers for Disease Control and Prevention. The Office was formed in 1998 and Dr Khoury served as the only ...

Recent developments – at national and international levels – in the regulation and governance of data, AI and medical devices are having significant impacts and potential impacts on the application of ...